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The online measurement of hemodialysis dose (Kt): Clinical
outcome as a function of body surface area.
Background. Recent advances enable the direct measure-
ment of small molecule clearance, Kecn, during each dialysis.
Average Kecn and treatment length, t, are multiplied giving to-
tal clearance, Kt. The body surface area (BSA) is a fixed trans-
formation of height and weight and is a well recognized measure
of body size. This project was conceived to search for clinical
outcome-based functions for measured Kt in terms of BSA to
enable simple Kt prescription guidelines for clinicians who are
able to measure Kecn, and to provide foundations for future
clinical research.
Methods. The data came from Fresenius Medical Care (NA)
files and included more than 32,000 patients with height, weight,
and paired Kecn and t measurements during December 2002.
Measurements were averaged for the month and used as pre-
dictor measures in Cox models of survival time during 2003.
Candidate Kt values from 30 L/treatment through 70 were ex-
amined to determine the best statistical fit for quintile and decile
delimited BSA groups evaluating the best fit Kt treatment target
for each group. Functional forms representing the relationship
between target Kt values and mean BSA of the groups were
then evaluated to determine the best fit.
Results. Kt targets increased with BSA in a curvilinear way
such that the rate of increase is greater at low BSA than high.
The best statistical fit was a double reciprocal form, Kt = 1/(a +
b/BSA); “a” and “b” are statistically derived coefficients. The
form has an appealing mathematical property; Kt approaches
0 as BSA approaches 0. Other forms fit the data nearly as well,
however, and can be used to estimate Kt targets for patients
with different BSA.
Conclusion. Empirical, outcome-based functions of mea-
sured Kt in terms of BSA exist and can be used as aids for
prescribing and judging hemodialysis treatment.
Current methods for judging hemodialysis dose
evolved from mathematical models of urea kinetics [1].
The solution to those equations gives rise to a treatment
ratio [2], Kt/V, values for which are commonly used as
therapeutic targets [3, 4]. Total dose per treatment (Kt)
is the product of dialyzer small molecule (urea) clearance
(Ku) and the length of the treatment (time: t) that is di-
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vided by an estimate of the urea distribution volume in the
body (Vu) yielding the ratio. Ku and Vu are not measured
directly in this system. Rather, Ku is typically estimated
from membrane properties (the overall mass transfer co-
efficient and membrane surface area, KoA) and dialysis
operating parameters (blood flow rate and dialysate flow
rate), then used with known values for t, blood urea ni-
trogen (BUN) values, and body weights before and after
a dialysis treatment, and the dialysis schedule in a mathe-
matical system that solves in iterative fashion for the un-
known value of Vu. A Kt/V value can then be estimated
from the results of those calculations [5].
Algebraic approximations have been developed as al-
ternative tools to estimate a Kt/V and require knowledge
of only t, fractional body weight change during treatment,
and the BUN concentrations [4, 6, 7]. Iterative and al-
gebraic methods are sometimes combined to estimate a
Kt/V [8, 9]. A simple quantity comparable to the Kt/V
and also calculated from BUN concentrations, the urea
reduction ratio (URR), is also used to evaluate treatment
[10, 11]. Those methods are part of accepted guidelines
for judging dialysis treatment [4] and have contributed
to better understanding of dialysis therapy over the years
that may have led in turn to lower mortality among pa-
tients [12]. All methods, however, are based on BUN
measurements and are not direct measurements of Ku,
t, or Vu. All except the URR require substantial calcu-
lation. As such, the frequency of estimating dialysis dose
has generally been limited to once monthly.
The urea kinetic methods were born and evolved dur-
ing a period of time when the convenient measurement of
small molecule dialyzer clearance during treatment was
impractical or impossible. All contemplate a value for Vu
but a number of methods are available for estimating Vu.
All anthropometric methods [13, 14, 15] use height and
weight as primary inputs but the exact numerical value
depends on the equation used. Several urea kinetic-based
methods are also available including estimates of 1 and 2
pool volumes [16]. Thus, a number of possible V values
are available for a patient at any particular time depend-
ing on the method use for its estimation. Furthermore, the
properties of Vu have recently come to question. Once
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thought to simply equal total body water (TBW or V),
Vu now appears to be less than V in patients with chronic
renal failure [17] but larger than V in patients with acute
renal failure [9, 18].
Finally, the theoretical foundation on which the urea
kinetic equations are based has been recently questioned
when they are used to evaluate a clinical outcome, like pa-
tient survival, instead of BUN concentrations, for which
they were originally designed [19]. The equations pre-
sume that the biological properties of V are limited to
those of a diluent for urea. V, however, is a proxy for body
mass that is associated with survival in dialysis patients
[19]. Thus, the true biological nature of Vu is ambiguous
and using a V as a proxy for “measured” body size by
which to evaluate measured Kt is uncertain. The value
for BSA, on the other hand, is fixed and certain, given
weight and height, for any patient on any given day. We
therefore chose it as the most reliable body size measure
by which to evaluate measured Kt in these studies.
Recent technical advances permit direct measurement
of small molecule clearance, called an effective on-line
conductivity (or ionic) clearance (Kecn), during the
course of each treatment [20–23]. The average Kecn is
multiplied by t at the end of treatment to give a mea-
sured Kt. Therapeutic-dosing schedules and physiologic
functions are often indexed to body size as weight or body
surface area (BSA) in clinical medicine. The purpose of
this project, then, was to see if clinical outcome (death
hazard) based empirical functions of measured Kt could
be mapped on BSA (f : Kt→BSA) to facilitate the mon-
itoring and prescription of treatment in centers able to
perform Kecn measurement and further to identify pos-
sible forms of such functions for future research.
METHODS
The technology supporting online clearance (OLC)
measurements is incorporated in the 2008H and 2008K
dialysis hardware systems manufactured by the Medi-
cal Products Division of Fresenius Medical Care (NA),
Lexington, MA, USA. The measurement method is
well reviewed elsewhere [24]. Measurements of Kecn, t,
height, and body weight collected during December 2002
were extracted from the FMC (NA) data files for those
33,328 patients with at least 1 Kecn and paired t mea-
surement. Kecn was multiplied by t to give measured Kt
for each treatment. BSA (m2) was calculated from body
weight (kg) and height (cm) according to the DuBois and
DuBois equation [25]
BSA = Weight0.425 × Height0.725 × 0.007184
Values for Kt and BSA were averaged and used as
death risk predictor measures for patients treated 3 times
weekly. Complete data were available for 32,763 patients,
who are the subject of this report. Survival time was mea-
sured for the calendar year 2003 and evaluated by the Cox
method. The analytical strategies have been described be-
fore [26, 27].
The primary analysis proceeded in 2 parts. The purpose
of the first was to explore general relationships among
treatment parameters, body size, and death risk in a pre-
liminary way. The purpose of the second was to evalu-
ate the possibility of constructing a Kt adequacy target
function of BSA, f : Kt→BSA, embodied as an empirical
formula that might be used clinically to estimate differ-
ent outcome based Kt targets for persons with different
BSA. As a supplementary analysis, we also compared
the findings evolving from these data with similar analy-
ses of older data that estimated Kt from BUN measure-
ments [26]. Finally, we evaluated current clinical practice
in terms of 1 f : Kt→BSA resulting from our evaluation
of these data.
Exploratory analyses
The statistical distributions of relevant measures in
the patient population and certain associations among
them were evaluated in preliminary fashion using stan-
dard methods. Death risk profiles were constructed for
BSA and Kt before and after certain statistical adjust-
ments as we have done before [26, 27] to explore visually
the general forms of the relationship between death risk
and those measures. We also constructed similar profiles
for patients grouped by BSA quintile. Such exploratory
analyses are necessary prerequisites for the use of spline
functions to see whether or not flex points in curves can
be evaluated. The use of such techniques is futile, after all,
if the relationship between 2 quantities is strictly linear
or if there is no relationship at all.
Estimating Kt targets by BSA
Flex points in the death hazard by Kt risk profiles were
estimated for BSA quintiles and deciles by a spline func-
tion analysis that has been described before [28, 29]. The
analyses assumed 2-segment functions in which death
hazard decreases with increasing Kt until it reaches a flex
point, threshold, target, or knot, after which the curve
tends to flatten. The goodness of fit to Cox models was
evaluated in Kt increments of 1.0 L/treatment from 30
L/treatment to 70 using the conditional transformation,
(Kt − x)+ =
{
0, Kt ≥ x
Kt − x, Kt < x
Kt is the Kt value at which each patient was treated; x
is a candidate Kt target; the “+” subscript indicates that
the term is truncated. The transformation creates a de-
viate from the candidate, x, for each patient such that
the value of (Kt—x)+ equals 0 for values at and above x
and equals (Kt—x) for values below x. The distributions
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of values in the population (e.g., the mean and standard
deviation) do not effect this transformation. The values
of (Kt—x) are either the difference between the patient
and candidate values or 0 as specified by the equation so
is independent of the mean of the values. A Cox model
was performed for each candidate Kt target (70–30 +
1 = 41 models) for each BSA group and the candidate
associated with the highest chi-square statistic (i.e., the
best fit) was selected as the target for that group. The
chi-square statistic functions here to indicate a good-
ness of fit between survival time and a measure of in-
terest like age, race, or the candidate thresholds, much as
the R2 statistic reflects goodness of fit in ordinary least
squares regression. Higher values indicate better fit. The
chi-square curves for all BSA groups except the fourth
decile group showed statistically significant values, sug-
gesting a single maximum value that was preceded by
a monotonic increase before and a monotonic decrease
after the peak and were used for these analyses. See
Figure 3 for examples.
Least squares regression analyses of Kt target by the
mean BSA of each BSA group were performed to evalu-
ate possible associations of the target with BSA. Several
mathematical forms were evaluated to see which if any
suggested a best fit. The forms were linear (Y = a + bX,
where “Y” means the Kt target; “X” means BSA; “a”
and “b” are statistically derived coefficients), exponential
(Y = exp[a + bX]), reciprocal of BSA (Y = a + b/X),
reciprocal of Kt (Y = 1/[a + bX]), double reciprocal
(Y = 1/[a + b/X]), multiplicative (Y = aXb), square root
of BSA (Y = a + b[X1/2]), square root of Kt (Y = [a +
bX]1/2), S-curve (Y = exp[a + b/X]), and quadratic
(Y = a + b1X + b2X2). The idea was to identify the
general forms of possible relationships between Kt tar-
get and BSA, to identify the best statistical fit among the
forms, and to recommend an easily understood general
form to assist the prescription of dialysis treatment.
Supplementary analyses
An earlier study that estimated Kt from BUN mea-
surements, instead of direct OLC measurement, found
that smaller persons required proportionately greater Kt
for their body sizes than larger patients [26]. Follow-up
analyses of those data evaluated Kt targets by quintiles
of both V and BSA using methods similar to those de-
scribed above. That exercise led to a preliminary linear
rule of thumb formula (Kt = 30 + 1/2V). The rule was
used to illustrate the way in which smaller persons may re-
quire greater Kt per liter of V than larger persons (Lowrie
EG: Kidney Int 63:1962, 2003) and to assist possible in-
terpretation of a clinical trial (Lowrie EG, et al. Kidney
Int 66:1291, 2004). We reevaluated those data examining
different mathematical forms for f : Kt→V and f : Kt→
BSA to determine the extent, if any, to which they are
comparable to the primary findings reported here.
Comparing an f : Kt→BSA with current clinical practice
The target Kt was estimated for selected patient groups
using a representative f : Kt→BSA and compared to the
Kt actually received. A similar comparison is made for
males and females treated in a large national trial (the
HEMO study) using published information [30].
RESULTS
We will first describe the preliminary explorations in-
cluding a description of the patient population and death
risk profiles observed among them. We then estimate Kt
targets as functions of BSA. Those primary findings are
then supplemented by comparing them to information
derived from our earlier studies [26]. Finally, we evalu-
ate current clinical practice in terms of one of the ways
identified to describe f : Kt→BSA.
Preliminary analyses
Table 1 describes the distributions of relevant parame-
ters in this patient population. The average dialysis time
was about 3.6 hours (interquartile range 3.4 to 4.0 h). The
average Kt was 50.7 L/treatment (interquartile range 43.7
to 57.5). Eighty percent of patients were treated between
37.7 L/treatment and 63.8. Slightly more than one half of
patients were male and slightly less than one half were
white. Forty-six percent (46%) were diabetic. The mean
BSA was 1.85 m2 and 98% of patients had BSA between
1.33 m2 and 2.53.
All treatment measures (Kecn, t, and Kt) were directly
correlated with all measures of body size (height, weight,
and BSA). The association of measured Kt with BSA
was significant [R2 = 0.258, P < 0.01; Kt = 12.0 (±0.4
SE) + 21.0 (± 0.2 SE) × BSA] but the range of Kt at
any given BSA was substantial. While the average Kt at
the mean BSA was 50.8 L/treatment, for example, the
95% prediction limit at that BSA extended from about
33 L/treatment to 68.
Death risk by Kt and BSA. Figure 1 illustrates the risk
profiles for BSA and Kt. The BSA profile (left panel)
suggests continuing improvement of risk with increas-
ing BSA and is similar to such profiles reported in the
past. The profiles were similar whether or not they were
adjusted statistically for age, gender, race, and diabetic
status.
The Kt profiles (Fig. 1, right panel) compare the risk of
death among the deciles of Kt following various statistical
adjustments. They suggest improving risk with increas-
ing Kt for all models and were similar in form appear-
ing to plateau in the range of 50 to 60 L/treatment. The
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Table 1. Distributions of measures
Percentiles
Measure Mean or% SD 99th 90th 75th 50th 25th 10th 1st
Age years 61.1 14.8 88.0 79.0 73.0 62.0 51.0 41.0 25.0
Gender% male 52.8
Diabetes% yes 46.4
Race
% White 49.0
% Black 43.3
% Other 7.7
Height cm 167.9 11.4 193.0 182.0 175.0 168.0 160.0 154.0 139.0
Predialysis weight kg 79.3 21.0 143.2 106.5 90.5 76.1 64.6 55.7 43.5
Postdialysis weight kg 76.3 20.4 138.8 102.8 87.2 73.1 62.0 53.4 41.5
Kecn mL/min 232.3 36.7 307.0 275.0 257.0 236.0 211.0 183.5 131.0
t minutes 219.2 27.3 286.0 244.0 240.0 215.0 205.0 180.0 156.0
Kt L/treatment 50.7 10.4 76.9 63.8 57.5 50.5 43.7 37.7 26.6
BSA m2 1.85 0.25 2.53 2.18 2.01 1.83 1.67 1.54 1.33
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Fig. 1. Risk profiles for deciles of BSA (left panel) and Kt (right panel) with and without statistical adjustments. CM adjustment means age, gender,
race, and diabetic status.
possible exception to that generality is the unadjusted
profile, which may have continued to improve through-
out its range. Hazard ratios for the sixth and seventh
deciles and the ninth and 10th deciles were not differ-
ent statistically from the eighth decile (the reference
group, P > 0.05) for any of the 4 models shown in the
figure.
Figure 2 illustrates the risk profile curves by BSA quin-
tile. Visual review suggests that death risk tends to plateau
at higher Kt in the higher BSA quintiles. The second and
third quintiles appear out of sequence, however, and de-
ciding possible targets or making therapeutic recommen-
dations from these curves would be difficult.
Estimating Kt targets as functions of BSA
The best-fit survival models for the first, second, fourth,
and fifth quintiles of BSA are shown in Figure 3. Maxi-
mum chi-square values were observed for each of the 5
quintiles (3rd quintile 55 L/treatment; curve not shown).
The peaks of these curves, used to identify the maxi-
mum chi-square value, are sharper for some curves than
others.
The regression analyses of Kt target on the mean of
BSA for the quintiles of BSA indicated that the best fit
was to a reciprocal X form (R2 = 0.774, P < 0.05) followed
by the S-curve (R2 = 0.772, P < 0.05), double reciprocal
(R2 = 0.767, P = 0.05), log X (R2 = 0.740, P = 0.06),
and multiplicative (R2 = 0.734, P = 0.06) forms. Figure 4
illustrates the relationship for the reciprocal X form. The
linear form equation was Kt = 18.8 + 17.3 × BSA (R2 =
0.702, P = 0.08).
The evaluation of different regression models for the
deciles of BSA indicated a best fit for the double recipro-
cal form (R2 = 0.648, P < 0.01) followed by the S-curve
(R2 = 0.632, P = 0.01), multiplicative (R2 = 0.621, P =
0.01), reciprocal X (R2 = 0.613, P < 0.02), and log X (R2 =
0.601, P < 0.02) forms. The linear equation was Kt = 20.7
+ 16.2 × BSA (R2 = 0.599, P < 0.02). The double recip-
rocal form is illustrated by Figure 5.
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Fig. 2. Kt risk profiles for the quintiles of BSA showing log hazard
(Y-axis) by the mean of the Kt octile (X-axis). These profiles were not
adjusted for case mix. Case mix–adjusted profiles suggested similar re-
lationships.
Table 2 shows statistics for the best-fit model for the
quintiles, deciles, and the combination of quintiles and
deciles of BSA (top portion of the table). The statistics
for the double reciprocal form are also shown for the
quintile analysis. Finally, statistics of several forms for the
combined sample are shown in order of magnitude (left
to right) of their related R2 statistic. The table also shows
the Kt target values projected by the forms as functions
of BSA (bottom portion of the table).
Combining the Kt target and BSA values for the quin-
tiles and deciles of BSA provides a more robust evalua-
tion of the algebraic forms of fit between the measures.
The best fit was to a double reciprocal form followed in
order by the S-curve, reciprocal BSA, multiplicative, and
log BSA forms. The linear equation was Kt = 20.1 + 16.6
× BSA (R2 = 0.632, P < 0.01). Figure 6 illustrates the
double reciprocal relationship for the combined sample.
Figure 7 compares the 5 f : Kt → BSA relationships for
the combined sample shown in Table 2. The relationships
are extrapolated beyond the limits of the observed BSA
data but are constrained in a space where both measures
have positive values. The presentation allows evaluation
of the relationships as they approach the structural limits
of clinical possibility, where Kt and/or BSA approach 0.
The figure includes also the linear form of the relation-
ship for comparison. A 0-intercept linear form, estimated
from other data [30], is included to facilitate comparison
with a linear form in which a 0-intercept is forced like one
that is in common use today (i.e., the Kt/V).
The reciprocal X and log X curves intersect the BSA
axis at 0.7 m2 and 0.3 when Kt = 0. The linear equa-
tion intersects the Kt axis at Kt = 20.1 L/treatment when
BSA = 0. The double reciprocal, S-curve, multiplicative,
and linear forced 0-intercept forms approach or intersect
the origin where both Kt and BSA equal 0. The S-curve
approaches that origin, however, only after a substan-
tial change of direction at low BSA. Extrapolating the
curvilinear forms to high BSA suggests that the increase
of Kt per increase of BSA is less at high BSA than low.
Extrapolation of the linear forms to high BSA imply no
such flattening so that Kt becomes quite high, particularly
when the intercept is assumed to be 0.
The arrows superimposed on Figure 7 indicate the ap-
proximate first percentile (left arrow) and 99th percentile
(right arrow) limits of the BSA distribution for these data.
All of the curvilinear forms suggest comparable values for
Kt in terms of BSA within those limits, as suggested also
by Table 2.
Supplementary analysis: Comparison with earlier data
Figure 8 illustrates the best-fit double reciprocal (dark
line) and the linear fit (gray line) forms for f : Kt→V, taken
from data reported earlier [26]. The order of statistical
fit for the algebraic forms was: double reciprocal (R2 =
0.811, P < 0.05), S-curve (R2 = 0.803, P < 0.05), reciprocal
X (R2 = 0.794, P < 0.05), multiplicative (R2 = 0.777, P <
0.05), and log X (R2 = 0.772, P = 0.05). The linear form fit
was R2 = 0.737, P = 0.06. The thin, dashed line illustrates
Kt/V = 1.2 and is included for comparison.
These data were also evaluated in terms of BSA. The
order of statistical fit was: double reciprocal (R2 = 0.844,
P < 0.05), S-curve (R2 = 0.834, P < 0.05), reciprocal X (R2
= 0.823, P < 0.05), multiplicative (R2 = 0.821, P < 0.05),
and log X (R2 = 0.812, P < 0.05). The linear form fit was
R2 = 0.793, P < 0.05. The double reciprocal coefficients
for “a” and “b” were 0.0119 and 0.0182, respectively. The
projected Kt targets resulting from those are lower than
those suggested in Table 2, particularly at high BSA. They
are 33.2 L/treatment, 40.1, 47.6, 52.8, and 55.6 at BSA
values of 1.0 m2, 1.4, 2.0, 2.6, and 3.0, respectively.
Comparing f : Kt→BSA with current clinical practice
The mean and median target Kt calculated using the
double reciprocal equation (50.6 L/treatment and 50.5)
and actual Kt values (50.7 L/treatment and 50.5) were
close to each other. The lower quartile, median, and
upper quartile of differences (actual—target) were 5.4
L/treatment less, 0.40 more, and 6.0 more than target, re-
spectively. Table 3 compares treated to target values for
different subgroups of patients.
The mean BSA for diabetic and nondiabetic patients
was 1.87 and 1.82 m2, respectively, and the mean Kt at
which they were treated was 50.8 and 50.3 L/treatment.
The comparable Kt targets were 51.0 and 50.0, respec-
tively. Female subgroups were treated at Kt slightly less
than the targets implied by these data while male sub-
groups were treated at slightly higher Kt.
Information taken from the HEMO study [30] is in-
cluded in the table for comparison. Females in the
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Fig. 3. Death hazard fit curves by Kt target for the 1st, 2nd, 4th, and 5th quintiles of BSA. The best-fit target for the first through fifth quintiles
were 42 L/treatment, 50, 55 (curve not shown), 51, and 56, respectively.
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Fig. 4. The best-fit (reciprocal X) to Kt target for each BSA quintile
by the mean of BSA for that quintile. The dark solid line is the best-fit
relationship. The dashed lines indicate the 95% confidence interval for
the regression. The standard error of estimates was 3.0 L/treatment,
that is, 5.9% of the mean Kt at the mean BSA. See Table 2 for other
regression statistics.
standard treatment group were treated at Kt nearly 10 L/
treatment lower than target (21%). Males were treated
at 5.2 L/treatment less. Patients in the high-dose groups
were treated at higher Kt than these targets.
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Fig. 5. The best-fit (reciprocal X) to Kt target for each BSA decile
by the mean of BSA for that decile. The dark solid line is the best-fit
relationship. The dashed lines indicate the 95% confidence interval for
the regression. The standard error of estimates was 3.7 L/treatment,
that is, 7.3% of the mean Kt at the mean BSA. See Table 2 for other
regression statistics.
DISCUSSION
Technologic advances now enable measurement of
small molecule clearance, Kecn, during the course of each
hemodialysis treatment [24]. Thus, the total clearance
received during each treatment, Kt, can be measured
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Table 2. Comparison of the algebraic forms regression statistics and projections from equations
Quintiles Combined
Data Deciles
model 1/BSA 1/1/BSA 1/1/BSA 1/1/BSA S-curve 1/BSA Multip lnBSA
R2% 77.4 76.7 64.8 68.6 67.6 66.2 65.7 64.9
P value <0.05 0.05 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
Coefficient ba −61.0 0.0260 0.0225 0.0237 −1.15 −56.8 34.6 31.0
Coefficient aa 84.4 0.0055 0.0075 0.0069 4.56 82.0 0.63 32.0
BSA m2 Values of Kt L/treatment
1.0 23.4 31.6 33.3 32.7 30.0 25.2 34.5 32.0
1.2 33.5 36.7 38.0 37.6 36.4 34.7 37.7 37.6
1.4 40.8 41.4 42.3 42.0 41.8 41.5 42.6 42.4
1.6 46.2 45.8 46.3 46.1 46.3 46.5 46.3 46.5
1.8 50.5 49.9 49.9 49.9 50.2 50.5 49.9 50.2
2.0 53.9 53.8 53.2 53.4 53.5 53.6 53.5 53.5
2.2 56.6 57.5 56.3 56.7 56.4 56.2 56.6 56.4
2.4 58.9 60.9 59.1 59.7 58.9 58.4 59.8 59.1
2.6 60.9 64.2 61.7 62.5 61.1 60.2 62.9 61.6
2.8 62.6 64.7 64.2 65.2 63.9 61.7 65.9 63.9
3.0 64.0 70.2 66.5 67.7 64.9 63.1 68.8 66.0
The dashed lines bracketing BSA 1.4 through 2.4 are the approximate 98% distribution interval for BSA. Values outside of the dashed lines are extrapolations
beyond those data limits to allow comparison of the estimates. Reciprocal BSA (1/BSA): Y = a + b/X; double reciprocal (1/1/BSA): Y = 1/(a + b/X); S-curve (S-curve):
Y = exp(a + b/X); multiplicative (multip): Y = aXb; log of BSA (ln BSA): Y = a + b(ln X)
aThe coefficients “a” and “b” are coefficients in the 4 equations.
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Fig. 6. The best-fit (double reciprocal) to Kt target for each BSA quin-
tile and decile by the mean of BSA for that quintile or decile. The dark
solid line is the best-fit relationship. The inner dashed lines indicate the
95% confidence interval for the regression. The standard error of es-
timates was 3.2 L/treatment, that is, 6.3% of the mean Kt at the mean
BSA. See Table 2 for other regression statistics.
directly. Two companies (Fresenius Medical Care, AG,
Bad Homburg, Germany and Lexington, MA, USA;
Gambro, AB, Stockholm, Sweden and Lakewood, CO,
USA) offer the capability, and other technologies have
been proposed [31] to support the goal. The body sur-
face area of patients is an unambiguous transformation
of measured height and weight [25] that is commonly
used to evaluate physiologic functions [32]. This study
was conceived and executed to see if empirical, clinical
outcome-based functions of Kt in terms of BSA could be
identified.
The studies suggest that higher total dialysis dose per
treatment, Kt, is required for persons of large body size
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Fig. 7. Comparison of extrapolated curves for the double reciprocal
(thick, black curve), S-curve (thick, dark gray curve), reciprocal X (thin,
gray curve), multiplicative (thick, light gray curve), and log X (thin,
black curve) forms. The linear form for these data is also shown (thin,
dash—dot—dash line). A linear, 0-intercept form taken from a regres-
sion of the mean BSA and mean Kt for males and females in the standard
treatment arm of the HEMO study [30] through the 0,0 origin is pro-
vided for comparison (thin, dashed line). The vertical arrows indicate
the approximate 98% distribution interval of BSA.
than small. The finding is not surprising, but to the best of
our knowledge has not been demonstrated before using
independent estimates of dose and size.
The mathematical forms of the empirical best fit rela-
tionships identified here appear curvilinear, bowing up-
ward such that the increase of “necessary” Kt increases
with BSA more rapidly at low BSA than high. Thus,
the target Kt/BSA is higher for small than large persons.
For example, the Kt projected for persons with BSA =
1.0 m2, 2.0, and 3.0 from the double reciprocal form
are 32.7 L/treatment, 53.4, and 67.7, giving Kt/BSA =
32.7 L/m2, 26.7, and 22.6, respectively. Similarly, Figure 8
suggests that the target Kt at V = 25 L, 40, and 55 are
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Fig. 8. The double reciprocal best-fit (black curve: R2 = 0.811, P <
0.04) and linear (gray line: R2 = 0.737, P = 0.06; Kt = 28.6 + [0.46 ×
BSA]) relationships for Kt target by volume of distribution (V) taken
from data reported earlier [26]. A 0-intercept, linear relationship Kt =
0 + [1.2 × V] is shown for comparison (dashed line).
38 L, 48, and 53, corresponding to Kt/V values of
1.52, 1.20, and 0.96, respectively. These findings are en-
tirely consistent with earlier observations, suggesting that
smaller patients require proportionately greater Kt for
their body sizes than larger patients [26, 27].
The most appealing mathematical form considered
here is the double reciprocal construct, for at least 2 rea-
sons. First, 4 of the 5 analytical sets (quintiles, deciles,
combined, supplementary V, and supplementary BSA)
evaluated here fit that construct best. Second, the form
approaches the 0,0 origin when BSA is extrapolated to
very low values.
It is clinically reasonable to presume that 0 total clear-
ance should be required at BSA = 0. HEMO study inves-
tigators opined similarly. Females treated in the standard
therapy arm of their study [30] experienced marginally
worse survival than males, and they suggested that the
difference could be explained physiologically by a non-
linear relationship with a 0 intercept such as a “power
function” (Depner T, et al. Kidney Int 66:1292, 2004). The
reciprocal BSA and log BSA forms reported here suggest
that a negative Kt is needed when extrapolated to low
BSA. The linear form suggests that about 20 L/treatment
would be required when BSA = 0—a form to which the
HEMO investigators appropriately objected. The dou-
ble reciprocal construct is a nonlinear form in which
the Kt target approaches 0 in a smooth and continuous
way as BSA approaches 0, as the investigators suggested.
That is a mathematical property of Y = 1/(a + b/X) be-
cause (a + b/X) approaches infinity as X approaches 0
and 1/(a + b/X) approaches 0 as (a + b/X) approaches
infinity.
The HEMO study investigators based their opinion in
part on a universal scaling law that relates physiologic
functions across mammalian species to a power function
of body mass [33, 34]. That power function is the same
as our multiplicative model, Y = aXb [34]. Four of our
5 analyses suggested a significant multiplicative relation-
ship between Kt target and BSA, and the fit was nearly
significant for the fifth, even though it was not the best-
fit relationship for any. The multiplicative form, like the
double reciprocal form, is curvilinear and forces the rela-
tionship to the 0,0 origin because 0b equals zero. The uni-
versal scaling law contemplates an increase of glomerular
filtration rate proportional to body mass raised to the 3/4
power. Our quintile, decile, and combined sample analy-
ses implied that the powers to which BSA was raised to
achieve target Kt values were 0.67, 0.60, and 0.63, respec-
tively. As such, these findings may find theoretical foun-
dation in current physiologic concepts about the cross
species scaling of physiologic functions [34].
Requiring a linear equation with a zero intercept for f :
Kt→BSA, similar to the conventional Kt/V construct for
example, leads to undertreatment for small patients or to
very high treatment recommendations for large patients,
depending on the slope for the equation. All of the curvi-
linear forms illustrated here give comparable estimates
of Kt target values within the range of BSA studied here,
however, theory not withstanding. As such, any of them
can be used for clinical purposes provided that the pa-
tient’s BSA is in or near that range.
The mathematical forms of f : Kt→BSA identified from
direct measurement of Kt and our approximation of it
from BUN measurements were similar but the target Kt
projected from them were different. The BUN-based tar-
gets were lower than the measured targets, particularly
at high BSA. There are several possible reasons for the
apparent discrepancy.
First, the Kt estimates from the 2 studies might not
be comparable because earlier studies based on pre and
post dialysis BUN measurements could reflect an effec-
tive Kt, Ket, while the OLC measurements could reflect a
higher, dialyzer Kt, Kdt. A Ket might be lower than a Kdt
due to the recirculation of freshly dialyzed blood through
the dialyzer, for example. Reports, however, have sug-
gested that Kecn is often less than the Kd for urea and
the matter has been recently discussed in substantial de-
tail [24]. Kecn reflects the effective clearance of urea from
the blood and not the dialyzer clearance of urea even
over a wide range of recirculation fractions to include
the purposeful reversal of the arterial and venous blood-
lines [24]. The important point here is that Kecn reflects
an effective small molecule clearance that is actually de-
livered to a patient more than it does a dialyzer clearance
that one might determine from evaluations of dialyzer
performance or from manufacturers’ specifications.
Our earlier investigations [26] were taken from mea-
surements of predialysis and postdialysis BUN concen-
trations and, thus, were also patient and not dialyzer
oriented. As such, they are comparable to the OLC
measurements. It is therefore unlikely that the difference
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Table 3. Clinical practice and the Kt target
Current practice Differenceb
Analysis
Gender Race BSA Kt Kt target L/Rx %
This studya
Patients All 1.85 50.6 50.5 0.1 0.12
Gender Males 1.94 53.9 52.2 1.7 3.24
Females 1.74 47.0 48.7 −1.7 −3.32
Race Black 1.88 51.7 51.1 0.6 1.14
White 1.84 50.0 50.4 −0.4 −0.69
Other 1.73 48.1 48.4 −0.3 −0.30
Diabetes Yes 1.82 50.8 51.0 −0.2 −0.27
No 1.87 50.3 50.0 0.3 0.58
Race by gender Black males 1.97 55.6 52.9 2.7 5.39
Black females 1.79 48.1 49.5 −1.4 −2.75
White males 1.93 53.1 52.1 1.0 1.93
White females 1.72 46.3 48.2 −1.9 −3.91
Other males 1.82 50.8 50.1 0.7 1.72
Other females 1.62 45.0 46.4 −1.4 −2.67
HEMO studya
Standard dose Males 1.83 45.5 50.7 −5.2 −10.26
Females 1.68 38.2 48.1 −9.9 −20.58
High dose Males 1.83 59.6 50.7 8.9 17.55
Females 1.68 51.7 48.1 3.6 7.48
a The Study statistics for both current practice and Kt targets are the means taken over all patients in each patient group. The HEMO statistics were taken from the
literature [30]. The Kt targets were calculated from the mean BSA for that HEMO study group.
b Kt—Kt target and 100 × (Kt—Kt target)/Kt target, respectively. L/Rx means L/treatment.
between Kt targets resulting from these and the earlier
studies evolved from the measurement of a Kd in one
case and a Ke in the other.
Second, the apparent discrepancy between the Kt tar-
get projections from our OLC and BUN data sets might
involve our choice of the estimate for V to calculate a
Kt from a Kt/V [26]. We estimated V by the Chertow
method [13]; kinetic estimates of V are said to be lower
than the Chertow estimates [17]. If so, our estimates of Kt
targets based on BUN measurements would be too high
all else equal. The explanation therefore seems unlikely
since the BUN-based targets were lower.
Finally, the reference point for estimating Kt during
this project was different from the earlier project [26].
This project relied on direct measurements of effective
small molecule clearance at the patient-dialyzer interface,
as explained above and elsewhere [24]. The BUN-based
estimate [26] reflected an apparent urea clearance from 1
pool of a complex multipool volume that can be approxi-
mated using a variety of different methods. We used only
1 of those methods [26]. A root cause of the difference
might be found in the different characteristics of the ref-
erence points and/or the data sets. In any event, the curvi-
linear form of the death hazard–based f : Kt→BSA was
similar in both, and similar also to the f : Kt→V, even if the
targets projected by them were somewhat different. Fur-
ther, direct measurements should take preference over
algebraic approximations. Finally, our goal here was to
evaluate outcome-based f : Kt→BSA using OLC-derived
information, not BUN measurement–derived estimates.
The f : Kt→BSA strategies for prescribing and judging
treatment are easily implemented in the clinical setting
for those facilities supporting the on-line measurement of
small molecule clearance. The BSA is easily calculated.
The target Kt can then be chosen from a table like that
illustrated in the Appendix. Values that are equivalent
for practical purpose also can be calculated from the log
X equation form, Kt = 32 + 31(ln BSA). Achievement of
the target Kt then can be monitored with each and every
treatment by OLC.
Implementation strategies are somewhat more difficult
for clinicians who cannot measure Kecn. A target Kt can
be selected from f : Kt→BSA, however. That Kt can be
prescribed from the length of treatment and a clearance
value estimated from manufacturers’ specifications for
the dialyzer (the KoA), blood flow rate, and dialysate
flow rate. The URR resulting from such a prescription
can be converted to a Kt/V by a variety of methods (e.g.,
Kt/V = ln [1–URR/100]) that can be multiplied by an
estimate of V (e.g., the Chertow V [13]), yielding a Kt, as
has been done elsewhere [26], to check the prescription.
The Kt at which these patients were treated was on
average close to the target value calculated for them.
Clinicians tend to prescribe more Kt than required by
a fixed Kt/V or URR rule because higher URR and,
therefore, Kt/V, is administered to small patients than
to large patients [35]. Hence, clinical judgment appears
to lead clinicians toward conclusions, suggesting that rel-
atively more treatment is required for smaller persons
than large—quite similar to these and other findings [26,
27]. Thus, the findings reported here may provide sup-
port for the role of clinical judgment in medical practice.
Treatment in patient groups with higher BSA, however,
tended to be at Kt values somewhat higher than target
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while groups with lower BSA tended to be treated at
values somewhat lower than target. Males, for example
were treated at 1.7 L/treatment higher than target (3.2%)
while females were treated at 1.7 L/treatment less than
target (−3.3%). Even so, the differences between current
practice and estimated target were relatively small on
average.
We are not able to say how Kt was estimated in the
HEMO study [30], but it was not by the methods used
here. Thus, the Kt values are not strictly comparable.
Nonetheless, it is interesting to note that females treated
in the standard dose arm of the study appear to have
been treated at Kt more than 20% lower than the tar-
get implied by these data. Males were treated at Kt only
about 10% less than the target. The HEMO data sug-
gested that females in the standard dose arm of the study
had marginally worse survival than did the other 3 groups
[30] and, thus, they may have been relatively undertreated
when judged by curvilinear Kt target criteria like those
implied by data like these.
These findings should be qualified in several ways. First,
they are empirical—finding equations that best fit the
data. As such, different data could lead to different equa-
tions. The theory supporting our choice of the double
reciprocal form is appealing. The mathematical forms
of our OLC-measured and BUN-estimated Kt targets
were both double reciprocal, but the projections result-
ing from them were different. Thus, different Kt measure-
ment techniques can lead to different target estimates for
the same BSA.
Second, all statistical estimates are vulnerable to the
methods used. There may be other ways to estimate the
targets for our BSA and V groups. Furthermore, there
is no assurance that the statistical best fit among the 41
Cox models evaluated for each group was indeed the true
target. It is nonetheless interesting and reassuring that
statistically ordered curvilinear relationships between Kt
target and BSA could be demonstrated for all of our sam-
ples, even those with only 3 degrees of freedom—5 data
pairs.
These findings should be confirmed or modified by fur-
ther study. Analytical methods that permit evaluation of
targets for different groups within a single survival model
may become commonly available and could measurably
facilitate an exercise like this.
CONCLUSION
These data suggest that there exist curvilinear
outcome-based relationships between BSA and Kt. The
relationships reported here can be easily implemented at
no incremental cost in dialysis facilities supporting the
online measurement of small molecule clearance.
APPENDIX. Minimum total
treatment (Kt) targets by body
surface area (BSA) double
reciprocal relationship
BSA Kt
1.20 37.6
1.22 38.0
1.24 38.5
1.26 38.9
1.28 39.4
1.30 39.8
1.32 40.3
1.34 40.7
1.36 41.2
1.38 41.6
1.40 42.0
1.42 42.4
1.44 42.9
1.46 43.3
1.48 43.7
1.50 44.1
1.52 44.5
1.54 44.9
1.56 45.3
1.58 45.7
1.60 46.1
1.62 46.5
1.64 46.9
1.66 47.3
1.68 47.7
1.70 48.0
1.72 48.4
1.74 48.8
1.76 49.2
1.78 49.5
1.80 49.9
1.82 50.3
1.84 50.6
1.86 51.0
1.88 51.3
1.90 51.7
1.92 52.0
1.94 52.4
1.96 52.7
1.98 53.1
2.00 53.4
2.02 53.7
2.04 54.1
2.06 54.4
2.08 54.7
2.10 55.1
2.12 55.4
2.14 55.7
2.16 56.0
2.18 56.3
2.20 56.7
2.22 57.0
2.24 57.3
2.26 57.6
2.28 57.9
2.30 58.2
2.32 58.5
2.34 58.8
2.36 59.1
2.38 59.4
2.40 59.7
2.42 60.0
2.44 60.3
2.46 60.6
2.48 60.8
2.50 61.1
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BSA Kt
2.52 61.4
2.54 61.7
2.56 62.0
2.58 62.2
2.60 62.5
2.62 62.8
2.64 63.1
2.66 63.3
2.68 63.6
2.70 63.9
2.72 64.1
2.74 64.4
2.76 64.6
2.78 64.9
2.80 65.2
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